Arcutis Biotherapeutics Q3 2025 Earnings Report

Arcutis Biotherapeutics EPS Results

• Actual EPS: N/A
• Consensus EPS: -$0.09
• Beat/Miss: N/A
• One Year Ago EPS: N/A

Arcutis Biotherapeutics Revenue Results

• Actual Revenue: N/A
• Expected Revenue: $86.69 million
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Arcutis Biotherapeutics Announcement Details

• Quarter: Q3 2025
• Date: 10/28/2025
• Time: Before Market Opens
• Conference Call Date: N/A
• Conference Call Time: N/A

Arcutis Biotherapeutics (NASDAQ:ARQT) is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for immuno-inflammatory skin diseases. The company’s research and development efforts center on targeted treatments that address the underlying biology of conditions such as plaque psoriasis, atopic dermatitis, seborrheic dermatitis and vitiligo. Arcutis employs a precision-medicine approach to deliver topical therapies designed to improve efficacy and tolerability compared with existing treatment options.

In August 2022, Arcutis received U.S. Food and Drug Administration approval for ZORYVE™ (roflumilast) cream, the company’s first commercial product, indicated for the treatment of plaque psoriasis in adults. Arcutis is also advancing a pipeline of next-generation roflumilast formulations, including topical ointments and foams, for the treatment of atopic dermatitis and seborrheic dermatitis. Additional clinical-stage programs include selective kinase inhibitors and other small-molecule assets aimed at expanding the company’s portfolio of dermatology therapies.

Founded in 2017 and headquartered in Westlake Village, California, Arcutis has built a U.S. specialty commercial infrastructure to support the launch and market adoption of its products. The company is led by President and Chief Executive Officer Steven L. Gothel, whose leadership team brings extensive experience in dermatology drug development, regulatory affairs and commercial operations. Arcutis continues to collaborate with academic investigators and patient advocacy groups to advance its clinical programs and address unmet needs in dermatology.